101
|
Hosni A, Huang S, Chiu K, Xu W, Su J, Bayley A, Bratman S, Cho J, Giuliani M, Kim J, O’Sullivan B, Ringash J, Hansen A, De Almeida J, Monteiro E, Chepeha D, Gilbert R, Irish J, Goldstein D, Waldron J, Hope A. PO-0709: Postoperative salvage therapy for early recurrence in oral cavity squamous cell carcinoma. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31019-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
102
|
Shah A, Sims D, Madan S, Siddiqi N, Luke A, Saeed O, Patel S, Murthy S, Shin J, Watts S, Jakobleff W, Forest S, Vukelic S, Belov D, Puius Y, Minamoto G, Muggia V, Carlese A, Leung S, Rahmanian M, Leff J, Goldstein D, Jorde U. A Multidisciplinary Continuous Support Heart Team Approach Improves Survival in Continuous Flow LVAD Recipients. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
103
|
Chinnadurai T, Patel S, Sims D, Saeed O, Shin J, Madan S, Hanif W, Vukelic S, Borukhov E, Forest S, Rahmanian M, Carlese A, Leung S, Jakobleff W, Goldstein D, Jorde U. Primary Graft Failure is More Common in Patients Bridged to Heart Transplant with LVAD: Role of Early Peripheral ECMO. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.894] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
104
|
Luke A, Castillo C, Taveras M, Chinnadurai T, Rangasamy S, Goldstein D, Jorde U, Patel S. IPADS and LVADS: VAD Coordinator Telemonitoring. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
105
|
Elander NO, Aughton K, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Oláh A, Büchler MW, Greenhalf W. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br J Cancer 2018; 118:947-954. [PMID: 29515256 PMCID: PMC5931115 DOI: 10.1038/s41416-018-0004-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 12/21/2017] [Accepted: 01/04/2018] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. METHODS DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-fluorouracil/folinic acid (5FU/FA). RESULTS DPD tumour expression was associated with reduced overall survival (hazard ratio, HR = 1.73 [95% confidence interval, CI = 1.21-2.49], p = 0.003). This was significant in the 5FU/FA arm (HR = 2.07 [95% CI = 1.22-3.53], p = 0.007), but not in the gemcitabine arm (HR = 1.47 [0.91-3.37], p = 0.119). High hENT1 tumour expression was associated with increased survival in gemcitabine treated (HR = 0.56 [0.38-0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80-1.78], p = 0.390). In patients with low hENT1 tumour expression, high DPD tumour expression was associated with a worse median [95% CI] survival in the 5FU/FA arm (9.7 [5.3-30.4] vs 29.2 [19.5-41.9] months, p = 0.002) but not in the gemcitabine arm (14.0 [9.1-15.7] vs. 18.0 [7.6-15.3] months, p = 1.000). The interaction of treatment arm and DPD expression was not significant (p = 0.303), but the interaction of treatment arm and hENT1 expression was (p = 0.009). CONCLUSION DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine.
Collapse
|
106
|
Madan S, Patel SR, Vlismas P, Saeed O, Murthy S, Forest S, Jakobleff W, Sims D, Lamour JM, Hsu DT, Shin J, Goldstein D, Jorde UP. Outcomes of Early Adolescent Donor Hearts in Adult Transplant Recipients. JACC-HEART FAILURE 2017; 5:879-887. [DOI: 10.1016/j.jchf.2017.05.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 05/07/2017] [Accepted: 05/16/2017] [Indexed: 10/19/2022]
|
107
|
Mancini D, Goldstein D, Taylor S, Chen L, Gass A, DeLair S, Pinney S. Maximizing donor allocation: A review of UNOS region 9 donor heart turn-downs. Am J Transplant 2017; 17:3193-3198. [PMID: 28898542 DOI: 10.1111/ajt.14499] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Revised: 08/23/2017] [Accepted: 09/06/2017] [Indexed: 01/25/2023]
Abstract
This study was performed to determine if organ selection practices for heart utilization by Region 9 transplant programs were optimal, and to identify opportunities to increase local organ recovery. A retrospective review of de-identified region-wide donor data January 1, 2010 through December 31, 2013 was performed. Over the study period 537 heart donors were identified, of which 321 (60%) were transplanted. Two hundred-sixteen consented hearts were not used; 190 of these were not recovered, and 26 were recovered but not transplanted. Of these, 245/321 (76%) hearts were transplanted at one of 5 regional programs, 15 (5%) were transplanted out of region as primary offers, and 61 (19%) were turned down in region and exported. Of the 61 exported hearts, 43 were turned down in region for donor-related "quality" codes (UNOS 830, 833-837) by at least one program, the remaining 18 hearts were turned down for non-"quality" reasons, primarily histocompatibility and size. Only 5/43 exported were turned down for "quality" reasons by all regional programs offered the organ. A review of consented, not recovered donor offers suggested an additional 28 organs were possibly appropriate for transplant. Our review of regional turn-downs suggests transplant centers could potentially identify additional usable organs without compromising short-term outcomes.
Collapse
|
108
|
Kwan J, Su J, Huang S, Xu W, Yip K, Giuliani M, Bayley A, Kim J, Hope A, Ringash J, Cho J, McNiven A, Hansen A, Goldstein D, Aerts H, Waldron J, Haibe-Kains B, O'Sullivan B, Bratman S, Liu F. A Radiomic Prognostic Index Refines Risk Models for Distant Metastasis in HPV-Related Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.2053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
109
|
Chiu K, Huang S, Hosni A, Tong L, Xu W, Lu L, Bayley A, Bratman S, Cho J, Giuliani M, Kim J, Ringash J, Waldron J, Spreafico A, Irish J, Gilbert R, Gullane P, Goldstein D, O'Sullivan B, Hope A. Outcomes of Oral Cavity Cancer Patients Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
110
|
Chiu K, Huang S, Hosni A, Tong L, Xu W, Lu L, Bayley A, Bratman S, Cho J, Giuliani M, Kim J, Ringash J, Waldron J, Spreafico A, Irish J, Gilbert R, Gullane P, Goldstein D, O'Sullivan B, Hope A. Potential Impact of the 8th edition UICC/AJCC Staging in Oral Cavity Cancer Patients Treated With Surgery and Post-Operative Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
111
|
Watts KJ, Meiser B, Zilliacus E, Kaur R, Taouk M, Girgis A, Butow P, Kissane DW, Hale S, Perry A, Aranda SK, Goldstein D. Perspectives of oncology nurses and oncologists regarding barriers to working with patients from a minority background: Systemic issues and working with interpreters. Eur J Cancer Care (Engl) 2017; 27:e12758. [PMID: 28892208 DOI: 10.1111/ecc.12758] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/22/2017] [Indexed: 11/29/2022]
Abstract
This study aimed to ascertain the systemic barriers encountered by oncology health professionals (HPs) working with patients from ethnic minorities to guide the development of a communication skills training programme. Twelve medical and five radiation oncologists and 21 oncology nurses were invited to participate in this qualitative study. Participants were interviewed individually or in a focus group about their experiences working with people from minority backgrounds. All interviews were transcribed verbatim and analysed thematically. HPs encountered language and communication barriers in their interactions with patients and their families, which were perceived to impact negatively on the quality and amount of information and support provided. There was a shortage of, and poor processes for engaging, interpreters and some HPs were concerned about the accuracy of interpretation. HPs expressed a need for training in cultural awareness and communication skills with a preference for face-to-face delivery. A lack of funding, a culture of "learning on the job", and time constraints were systemic barriers to training. Oncologists and oncology nurses encounter complex challenges in clinical interactions with minority patients and their families, including difficulties working with interpreters. Formal training programmes targeted to the development of culturally competent communication skills are required.
Collapse
|
112
|
van Rijssen L, ter Veer E, Besselink M, Mali R, Berlin J, Boeck S, Bonnetain F, Conroy T, Deplanque G, Goldstein D, Glimelius B, Neoptolemos J, Reni M, Scheithauer W, van der Meer J, Wilmink J, van der Poel M, Busch O, van Oijen M, van Laarhoven H. COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
113
|
Sarfaty M, Moore A, Neiman V, Rosenbaum E, Goldstein D. Chasing the survival curve tail: The effect on cost-effectiveness of nivolumab for second-line treatment of advanced renal cell carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx375.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
114
|
Cubillo Gracian A, Dean A, Muñoz A, Hidalgo M, Pazo-Cid R, Martin M, Macarulla Mercade T, Lipton L, Harris M, Manzano-Mozo J, Maurel J, Guillen-Ponce C, Tebbutt N, Cooray P, Sohal D, Zalupski M, Kolevska T, Stagg R, Goldstein D. YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
115
|
Casali P, Le Cesne A, Poveda A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson I, Italiano A, Gelderblom H, Penel N, Kopp HG, Goldstein D, Broto JM, Gronchi A, Wardelmann E, Marreaud S, Zalcberg J, Litière S, Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
116
|
Goldstein D, Shalev V, Goldshtein I, Weil C, Bourvine L, Koren S, Chodick G. Anti-Cholinergic Treatment for Overactive Bladder in a Large Health Provider. Clin Ther 2017. [DOI: 10.1016/j.clinthera.2017.05.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
117
|
Madan S, Saeed O, Shin J, Sims D, Goldstein D, Piña I, Jorde U, Patel SR. Donor Troponin and Survival After Cardiac Transplantation: An Analysis of the United Network of Organ Sharing Registry. Circ Heart Fail 2017; 9:CIRCHEARTFAILURE.115.002909. [PMID: 27329985 DOI: 10.1161/circheartfailure.115.002909] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 04/28/2016] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite a limited supply of organs, only 1 in 3 potential donor hearts is accepted for transplantation. Elevated donor troponin levels have generally been considered a contraindication to heart transplantation; however, the data supporting this practice are limited. METHODS AND RESULTS We identified 10 943 adult (≥18 years) heart transplant recipients in the United Network of Organ Sharing (UNOS) database with preserved donor left ventricular ejection fraction (≥50%) and where peak donor troponin I values were available. When analyzed as a continuous variable, there was no association between peak donor troponin levels and recipient mortality up to 1 year follow-up in unadjusted (hazards ratio, 0.999; 95% confidence interval, 0.997-1.002; P=0.856) and adjusted Cox models (hazards ratio, 1.000; 95% confidence interval, 0.997-1.002; P=0.950). Next, we divided the entire cohort into 3 groups based on donor troponin I values: <1 ng/mL (n=7812), 1 to 10 ng/mL (n=2770), and >10 ng/mL (n=361). Using unadjusted and adjusted Cox models and Kaplan-Meier analysis, there was no significant difference in recipient mortality at 30 days, 1 year, 3 years, or 5 years between the 3 groups. Similarly, cardiac allograft vasculopathy up to 5 years and primary graft failure up to 30 days of follow-up post transplant did not differ between the 3 donor troponin groups. The median length of hospital stay post transplant was also similar across groups. CONCLUSIONS Elevated donor troponin I levels in the setting of preserved left ventricular ejection fraction were not associated with intermediate-term mortality, cardiac allograft vasculopathy, or primary graft failure rates in hearts accepted for transplantation. This finding could help expand the donor pool.
Collapse
|
118
|
Bekaii-Saab T, Goldstein D, Li C, Okusaka T, O’Neil B, Reni M, Tabernero J, Qin S, Van Cutsem E, Borodyansky L, Li C. CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx261.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
119
|
Madan S, Saeed O, Vlismas P, Katsa I, Patel S, Shin J, Sims D, Goldstein D, Jorde U. Outcomes for Donor Hearts with Low Ejection Fraction That Improve During Donor Management. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
120
|
Xia Y, Forest S, Friedmann P, Chou L, Patel S, Jorde U, Goldstein D. Factors Associated with Prolonged Survival in Destination Therapy LVAD Recipients. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
121
|
Uriel N, Colombo P, Cleveland J, Long J, Salerno C, Goldstein D, Patel C, Ewald G, Tatooles A, Silvestry S, John R, Caldeira C, Jeevanandam V, Boyle A, Sundareswaran K, Sood P, Mehra M. Hemocompatibility Related Outcomes in the Multicenter Study of Maglev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with Heartmate 3 (Momentum 3) Pivotal Trial. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
122
|
Hope A, Karamboulas C, Xu W, Huang S, Kim J, Bratman S, Cho J, Ringash J, Giuliani M, Bayley A, Waldron J, Perez-Ordonez B, Goldstein D, De Almeida J, Brown D, Irish J, Gullane P, Gilbert R, O'Sullivan B, Ailles L. OC-022: Association of patient derived xenograft formation with oral cavity squamous cell cancer outcomes. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30170-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
123
|
Xia Y, Friedmann P, Bello R, Goldstein D, D'Alessandro D. Does Lung Donation by Heart Donors Have an Impact on Survival in Heart Transplant Recipients? Am J Transplant 2017; 17:506-511. [PMID: 27457355 DOI: 10.1111/ajt.13981] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 06/24/2016] [Accepted: 07/18/2016] [Indexed: 01/25/2023]
Abstract
Lung procurement is increasing during multiorgan recovery and substantially alters the explant process. This study evaluated whether lung donation by a heart donor affects survival in heart transplant recipients. Retrospective analysis of United Network for Organ Sharing (UNOS) adult heart transplantation data from 1998 to 2012 was performed. Lung donors (LDs) were defined as those having at least one lung procured and transplanted. Non-LDs had neither lung transplanted. Heart transplant recipients who had previous transplants, who had heterotopic transplants, who were waitlisted for other organs or who were temporarily delisted were excluded from the analysis. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed. Of 23 590 heart transplant recipients meeting criteria during the study period, 8638 (36.6%) transplants were from LDs. Donors in the LD group had less history of cigarette use (15.5% vs. 29.5%, p < 0.001). On univariate analysis, LDs were associated with improved patient survival (p < 0.001). On multivariate analysis, LDs were not significantly associated with patient survival (adjusted hazard ratio 0.98, 95% confidence interval 0.94-1.03). Analysis of the UNOS registry suggested that donor pulmonary status and lung procurement had no detrimental effect on survival in heart transplant recipients, supporting the present practice of using donor lungs whenever possible.
Collapse
|
124
|
Minamoto GY, Lee D, Colovai A, Levy D, Vasovic L, Roach KW, Shuter J, Goldstein D, D'Alessandro D, Jorde UP, Muggia VA. False positive hepatitis C antibody test results in left ventricular assist device recipients: increased risk with age and transfusions. J Thorac Dis 2017; 9:205-210. [PMID: 28203425 DOI: 10.21037/jtd.2017.01.10] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Left ventricular assist devices (LVADs) have been successfully used in patients with heart failure. However, LVADs may trigger immune activation, leading to higher frequencies of autoantibodies. We describe the clinical, epidemiological, and laboratory characteristics of LVAD recipients with false positive hepatitis C (FPHC) serology among 39 consecutive adult LVAD recipients who bridged to heart transplantation from January 2007 to January 2013 at Montefiore Medical Center. FPHC patients were identified as those with post-LVAD positive hepatitis C ELISA antibody tests and negative confirmatory testing with hepatitis C RNA PCR and/or radioimmunoblot assay. Ten (26%) patients previously seronegative for hepatitis C were found to have FPHC after device placement. Of the 39 patients, 32 had HeartMate II devices. The mean age at LVAD placement was 55 years. FPHC correlated with older age at the time of LVAD implantation and with receipt of packed red blood cell transfusions, but not with gender, fresh frozen plasma transfusions, panel reactive antibodies, globulin fraction, rheumatoid factor, or anticardiolipin antibodies. Clinicians should be aware of this increased risk of FPHC in older LVAD patients and those more heavily transfused in order to avoid unnecessary apprehension and possible delay in transplantation. Further studies should be done to evaluate the possible relationship between transfused blood products and immunomodulation.
Collapse
|
125
|
Reches H, Erlich I, Dudnik E, Zer A, Goldstein D, Roisman L, Peled N. P3.07-007 Compassionate Use Program for New Cancer Drugs in Israel - Shortcut for Reimbursement Approval. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2016.11.2198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|